CD1D and acute myeloid leukemia: In vivo activation of iNKT cells with αGalCer similarly leads to a significant reduction in CD1d + AML (Supp Fig. 7b) burden in the blood, spleen, and bone marrow (Schematic Figs. 3e and 6f).